Exagen (XGN) Stock Price, News & Analysis

Company Overview

Exagen Inc. (NASDAQ:XGN) is a commercial-stage diagnostics company focused on autoimmune diseases. The company develops and provides blood-based testing services intended to help healthcare professionals diagnose, differentiate and manage systemic autoimmune conditions, particularly lupus and related rheumatic diseases.

Exagen’s flagship testing platform is AVISE, a panel-based diagnostic approach that combines multiple autoantibody and biomarker measurements. Its offerings include AVISE CTD, which supports the evaluation of connective tissue diseases, and AVISE Lupus, which is designed to help distinguish systemic lupus erythematosus from other autoimmune conditions. Exagen also provides additional testing and laboratory services for rheumatology practices.

Founded in 2002, Exagen operates a specialized clinical laboratory business serving physicians and patients in the United States. The company’s tests are generally ordered by healthcare providers and processed through its laboratory operations, with a primary focus on improving diagnostic clarity and treatment decisions in autoimmune care.

Key Stats

• Today's Range: $7.78 to $8.20
• 50-Day Range: $4.35 to $8.74
• 52-Week Range: $2.59 to $12.23
• Volume: 617,265 shs
• Average Volume: 255,155 shs
• Market Capitalization: $197.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.63
• Consensus Rating: Moderate Buy

Exagen Stock Analysis - MarketRank™

Exagen scored higher than 58% of companies evaluated by MarketBeat, and ranked 331st out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Exagen has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Exagen has a consensus price target of $9.63, representing about 17.8% upside from its current price of $8.17.

Amount of Analyst Coverage

Exagen has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Exagen are expected to grow in the coming year, from ($0.69) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Exagen is -10.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exagen is -10.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Exagen has a P/B Ratio of 10.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.69% of the float of Exagen has been sold short.

Short Interest Ratio / Days to Cover

Exagen has a short interest ratio ("days to cover") of 3.59, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exagen has recently decreased by 7.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exagen does not currently pay a dividend.

Dividend Growth

Exagen does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for XGN on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.

MarketBeat Follows

4 people have added Exagen to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Exagen insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:XGN
• CIK: 1274737
• Web: www.exagen.com
• Phone: 760-560-1501
• Fax: N/A
• Employees: 220
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Exagen: $9.63
• High Price Target: $12.00
• Low Price Target: $8.00
• Potential Upside/Downside: +17.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.95 million
• Net Margins: -26.61%
• Pretax Margin: -26.54%
• Return on Equity: -104.46%
• Return on Assets: -28.93%

Debt

• Debt-to-Equity Ratio: 1.96
• Current Ratio: 3.18
• Quick Ratio: 3.18

Sales & Book Value

• Annual Sales: $71.12 million
• Price / Sales: 2.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.77 per share
• Price / Book: 10.61

Miscellaneous

• Outstanding Shares: 24,225,000
• Free Float: 21,706,000
• Market Cap: $197.92 million
• Optionable: Optionable
• Beta: 2.12